<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Surg</journal-id><journal-id journal-id-type="iso-abbrev">Int J Surg</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">JS9</journal-id><journal-title-group><journal-title>International Journal of Surgery (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1743-9191</issn><issn pub-type="epub">1743-9159</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430850</article-id><article-id pub-id-type="pmcid-ver">PMC12430850.1</article-id><article-id pub-id-type="pmcaid">12430850</article-id><article-id pub-id-type="pmcaiid">12430850</article-id><article-id pub-id-type="pmid">40540545</article-id><article-id pub-id-type="doi">10.1097/JS9.0000000000002720</article-id><article-id pub-id-type="publisher-id">IJS-D-25-02550</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>Comprehensive analysis of tuberculosis burden trends and attributable risk factors in the BRICS countries from 1990 to 2021, with forecasts for the next 15 years</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xiaomeng</given-names></name><degrees>MBBS</degrees><email>z15893237381@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="M">Manru</given-names></name><degrees>MBBS</degrees><email>guomanru@henu.edu.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Song</surname><given-names initials="X">Xuefei</given-names></name><degrees>MM</degrees><email>389426190@qq.com</email><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdalla</surname><given-names initials="AE">Abualgasim Elgaili</given-names></name><degrees>PhD</degrees><email>gasimmicro@gmail.com</email><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="G">Guirong</given-names></name><degrees>MD</degrees><email>wangguirong1230@ccmu.edu.cn</email><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6825-9690</contrib-id><name name-style="western"><surname>Xie</surname><given-names initials="L">Longxiang</given-names></name><degrees>PhD</degrees><email>xielongxiang123@126.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>School of Basic Medical Sciences, Henan University, Kaifeng, China</aff><aff id="aff2"><label>b</label>Inner Mongolia Fourth Hospital, Hohhot, Inner Mongolia Autonomous Region, P.R. China</aff><aff id="aff3"><label>c</label>Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia</aff><aff id="aff4"><label>d</label>Department of clinical laboratory, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding authors. Address: School of Basic Medical Sciences, Henan University, Kaifeng 475004, China. Tel.: +86 0371-23880585. E-mail: <email>xielongxiang123@126.com</email> (L. Xie); Department of clinical laboratory, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China. Tel.: +86 010-89509361. E-mail: <email>wangguirong1230@ccmu.edu.cn</email> (G. Wang); Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia. Tel.: +966 539112018. E-mail: <email>aealseddig@ju.edn.sa</email>, <email>gasimmicro@gmail.com</email> (A. Abdalla).</corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>6</month><year>2025</year></pub-date><volume>111</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496813</issue-id><fpage>6050</fpage><lpage>6062</lpage><history><date date-type="received"><day>24</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0</ext-link> (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="js9-111-6050.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="js9-111-6050.pdf"/><abstract><sec><title>Background:</title><p>The study was to elucidate a comprehensive view of the burden of tuberculosis (TB) from different dimensions.</p></sec><sec><title>Methods:</title><p>Data were sourced from the Global Burden of Disease 2021. We provided a comprehensive overview of all relevant measures and the associated age-standardized rates per 100 000 (ASR) across BRICS countries. And we analyzed risk factors contributed to TB-related deaths and disability-adjusted life years (DALYs). Additionally, temporal trends in the disease were delineated using a joinpoint regression model, while projections over the subsequent 15&#160;years were generated using the Bayesian age-period-cohort model.</p></sec><sec><title>Results:</title><p>The global age-standardized incidence rate (ASIR) was 103 per 100 000 in 2021, which represented a 40.5% decrease since 1990. Notably, ASIR in China experienced a significant decline of 66.7%. Individuals aged 65 and above were high-risk group for TB. For the Russian Federation, the percentages of deaths and DALYs caused by multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis were approximately 30% and 14% respectively in 2021. Although DS-TB still accounted for the highest proportion of about 55%, it was significantly lower in contrast to other countries, where the rate reached over 80%. And the gradual downward trends of ASIR and ASMR are expected to continue over the period from 2021 to 2036.</p></sec><sec><title>Conclusions:</title><p>The results indicated that the burden of TB in BRICS countries has decreased over the past 30&#160;years. It highlights an urgent requirement to develop and implement relevant strategies in the prevention and control of TB based on country-specific development status.</p></sec></abstract><kwd-group><kwd>BRICS</kwd><kwd>Global Burden of Disease (GBD)</kwd><kwd>tuberculosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><title>Background</title><p>Tuberculosis (TB) represents a long-standing and persistent infectious disease which has afflicted humanity for millennia, posing a significant global threat to human health<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup>. The causative agent of this disease is the slow-growing bacterium <italic toggle="yes">M. tuberculosis</italic><sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup>. Due to the survival strategies of <italic toggle="yes">M. tuberculosis</italic> within host cells, coupled with its ability to evade the immune system, the control of TB prevalence is hindered, further aggravating the global TB burden<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup>. The rise of drug-resistant tuberculosis (DR-TB), notably including multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) increases the costs of diagnosing, treating and preventing TB, and imposes significant economic and social burdens on countries globally<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup>. In 2023, TB potentially regained its position as the leading cause of mortality attributed to a single infectious agent globally, after a three-year period during which it was surpassed by coronavirus disease (COVID-19)<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup>. With the implementation of the WHO&#8217;s End TB Strategy in 2014 and the UN Sustainable Development Goals established in 2015, both the UN and WHO have pledged to eliminate the TB epidemic by 2035<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup>. It is vital to comprehensively analyze TB burden trends and evaluate risk factors for tracking advancements toward the objectives of the End TB Strategy.<boxed-text id="UBT0001" position="float" orientation="portrait"><sec><title>HIGHLIGHTS</title><p>
<list list-type="bullet"><list-item><p>Tuberculosis burden stratified by BRICS-sex-age patterns and its associated risk factors were estimated.</p></list-item><list-item><p>In BRICS countries, tuberculosis (TB) incidence rates rose with age, peaking in the 45&#8211;69 age group, highlighting the higher burden of the TB in the elderly.</p></list-item><list-item><p>The proportion of drug-resistant TB in BRICS countries and different Socio-demographic Index (SDI) regions increased, especially in the Russian Federation.</p></list-item><list-item><p>A downward trend in TB across BRICS was observed by our prediction through 2036, especially in the Russian Federation and China, but more efforts will be necessary to meet the objectives of the End TB Strategy.</p></list-item></list></p></sec></boxed-text></p><p>BRICS countries, which include Brazil, the Russian Federation, India, China, and South Africa, are categorized together as they are all experiencing rapid economic growth. They account for almost half of the global population and are all high-burden countries for TB<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup>. Among BRICS countries, TB remains a major obstacle to public health. For instance, TB cases experienced a significant increase during the period from 2015 to 2019 in Brazil<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup>. In South Africa, it accounts for the deaths of 60 000 individuals each year<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup>. India accounted for 26% and China for 6.8% of all estimated incident cases of TB worldwide<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup>. Although each of them must cope with different challenges, BRICS countries are still recognized as leaders in TB control. They are the major financial source of TB management, providing much funding<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup>. The success of their TB control and treatment efforts is crucial for achieving the objectives of the global End TB Strategy (2016&#8211;2035).</p><p>While previous studies have examined historical TB mortality trends in BRICS using age-period-cohort analyses<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> and infectious disease mortality patterns<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup>, no comprehensive assessment has specifically addressed the TB burden and its attributable risk factors in BRICS. Adhering TITAN guidelines 2025 for transparent reporting<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup>, our study filled this critical gap by presenting the first comprehensive analysis of TB burden trends and attributable risk factors from 1990 to 2021, with forecasts for the subsequent 15&#160;years. This work not only advanced the understanding of evolving TB dynamics but also established an evidence base to monitor progress toward the WHO&#8217;s 2035 End TB Strategy targets. It further provided a framework for policy formulation and resource allocation strategies, ultimately contributing to public health TB prevention and control efforts.<table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>All-age cases and age-standardized incidence, prevalence, mortality, and DALYs rate of tuberculosis in global and BRICS countries in 1990 and 2021</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="left" colspan="1">Location</th><th rowspan="3" align="left" colspan="1">Measure</th><th colspan="2" align="center" rowspan="1">1990</th><th colspan="2" align="center" rowspan="1">2021</th></tr><tr><th align="left" rowspan="1" colspan="1">All-ages cases</th><th align="left" rowspan="1" colspan="1">Age-standardized rates per 100 000 people</th><th align="left" rowspan="1" colspan="1">All-ages cases</th><th align="left" rowspan="1" colspan="1">Age-standardized rates per 100 000 people</th></tr><tr><th align="center" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (95% UI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (95% UI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (95% UI)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (95% UI)</th></tr></thead><tbody><tr><td rowspan="4" align="left" colspan="1">Global</td><td align="left" rowspan="1" colspan="1">Incidence</td><td align="center" rowspan="1" colspan="1">8&#160;598&#160;520 (7&#160;528&#160;228, 9&#160;854&#160;794)</td><td align="center" rowspan="1" colspan="1">173.03 (152.88, 198.71)</td><td align="center" rowspan="1" colspan="1">8&#160;407&#160;133 (7&#160;519&#160;793, 9&#160;393&#160;767)</td><td align="center" rowspan="1" colspan="1">103 (92.21, 114.91)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence</td><td align="center" rowspan="1" colspan="1">1&#160;605&#160;364&#160;975 (1&#160;440&#160;332&#160;859, 1&#160;777&#160;421&#160;464)</td><td align="center" rowspan="1" colspan="1">30696.64 (27716.5, 33&#160;776.96)</td><td align="center" rowspan="1" colspan="1">1&#160;911&#160;816&#160;784 (1&#160;733&#160;433&#160;144, 2&#160;100&#160;447&#160;765)</td><td align="center" rowspan="1" colspan="1">23614.01 (21451.1, 26020.11)</td></tr><tr><td align="left" rowspan="1" colspan="1">Deaths</td><td align="center" rowspan="1" colspan="1">1&#160;778&#160;869 (1&#160;532&#160;822, 1&#160;980&#160;801)</td><td align="center" rowspan="1" colspan="1">39.99 (34.16, 44.76)</td><td align="center" rowspan="1" colspan="1">1&#160;162&#160;796 (1&#160;050&#160;008, 1&#160;313&#160;985)</td><td align="center" rowspan="1" colspan="1">13.96 (12.61, 15.72)</td></tr><tr><td align="left" rowspan="1" colspan="1">DALYs</td><td align="center" rowspan="1" colspan="1">82&#160;679&#160;773 (73&#160;004&#160;989, 91&#160;407&#160;746)</td><td align="center" rowspan="1" colspan="1">1650.59 (1457.64, 1824.72)</td><td align="center" rowspan="1" colspan="1">46&#160;977&#160;463 (42&#160;482&#160;994, 52&#160;463&#160;556)</td><td align="center" rowspan="1" colspan="1">580.26 (522.37, 649.82)</td></tr><tr><td rowspan="4" align="left" colspan="1">China</td><td align="left" rowspan="1" colspan="1">Incidence</td><td align="center" rowspan="1" colspan="1">1&#160;167&#160;808 (1&#160;359&#160;621, 1&#160;001&#160;441)</td><td align="center" rowspan="1" colspan="1">109.01 (124.61, 94.81)</td><td align="center" rowspan="1" colspan="1">617&#160;726 (688&#160;348, 549&#160;548)</td><td align="center" rowspan="1" colspan="1">36.28 (40.47, 32.63)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence</td><td align="center" rowspan="1" colspan="1">369&#160;779&#160;785 (420&#160;948&#160;319, 324&#160;342&#160;084)</td><td align="center" rowspan="1" colspan="1">31445.76 (35142.48, 27902.18)</td><td align="center" rowspan="1" colspan="1">491&#160;548&#160;380 (539&#160;371&#160;580, 445&#160;855&#160;387)</td><td align="center" rowspan="1" colspan="1">30557.45 (33531.31, 27692.69)</td></tr><tr><td align="left" rowspan="1" colspan="1">Deaths</td><td align="center" rowspan="1" colspan="1">171&#160;091 (204&#160;908, 141&#160;634)</td><td align="center" rowspan="1" colspan="1">20.09 (23.84, 16.68)</td><td align="center" rowspan="1" colspan="1">37&#160;332 (49&#160;368, 9309)</td><td align="center" rowspan="1" colspan="1">1.91 (2.51, 1.51)</td></tr><tr><td align="left" rowspan="1" colspan="1">DALYs</td><td align="center" rowspan="1" colspan="1">7&#160;325&#160;730 (8&#160;528&#160;411, 6&#160;221&#160;452)</td><td align="center" rowspan="1" colspan="1">719.42 (837.38, 610.63)</td><td align="center" rowspan="1" colspan="1">1&#160;375&#160;510 (1&#160;723&#160;072, 120&#160;820)</td><td align="center" rowspan="1" colspan="1">76.22 (94.45, 62.59)</td></tr><tr><td rowspan="4" align="left" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Incidence</td><td align="center" rowspan="1" colspan="1">71&#160;346 (61&#160;968, 82&#160;486)</td><td align="center" rowspan="1" colspan="1">55.37 (48.68, 63.34)</td><td align="center" rowspan="1" colspan="1">70&#160;946 (61&#160;021, 82&#160;901)</td><td align="center" rowspan="1" colspan="1">29.6 (25.57, 34.54)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence</td><td align="center" rowspan="1" colspan="1">49&#160;615&#160;965 (44&#160;325&#160;062, 54&#160;874&#160;448)</td><td align="center" rowspan="1" colspan="1">35058.16 (31768.14, 38390.52)</td><td align="center" rowspan="1" colspan="1">53&#160;710&#160;150 (47&#160;852&#160;330, 60&#160;341&#160;104)</td><td align="center" rowspan="1" colspan="1">22668.45 (20338.3, 25346.57)</td></tr><tr><td align="left" rowspan="1" colspan="1">Deaths</td><td align="center" rowspan="1" colspan="1">8526 (8276, 8783)</td><td align="center" rowspan="1" colspan="1">7.85 (7.58, 8.07)</td><td align="center" rowspan="1" colspan="1">5576 (5307, 5806)</td><td align="center" rowspan="1" colspan="1">2.24 (2.13, 2.33)</td></tr><tr><td align="left" rowspan="1" colspan="1">DALYs</td><td align="center" rowspan="1" colspan="1">419&#160;608 (402&#160;648, 438&#160;148)</td><td align="center" rowspan="1" colspan="1">328.64 (317.46, 341.19)</td><td align="center" rowspan="1" colspan="1">221&#160;135 (209&#160;212, 232&#160;047)</td><td align="center" rowspan="1" colspan="1">90.42 (85.49, 95.28)</td></tr><tr><td rowspan="4" align="left" colspan="1">India</td><td align="left" rowspan="1" colspan="1">Incidence</td><td align="center" rowspan="1" colspan="1">2&#160;656&#160;904 (2&#160;173&#160;904, 3&#160;262&#160;442)</td><td align="center" rowspan="1" colspan="1">392.62 (323.9, 477.11)</td><td align="center" rowspan="1" colspan="1">2&#160;955&#160;264 (2&#160;599&#160;262, 3&#160;383&#160;727)</td><td align="center" rowspan="1" colspan="1">214.39 (188.98, 244.86)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence</td><td align="center" rowspan="1" colspan="1">269&#160;840&#160;574 (227&#160;071&#160;987, 323&#160;383&#160;612)</td><td align="center" rowspan="1" colspan="1">31294.34 (26746.2, 36800.19)</td><td align="center" rowspan="1" colspan="1">379&#160;022&#160;522 (334&#160;241&#160;752, 424&#160;826&#160;762)</td><td align="center" rowspan="1" colspan="1">26792.21 (23701.88, 29963.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Deaths</td><td align="center" rowspan="1" colspan="1">600&#160;796 (533&#160;098, 680&#160;033)</td><td align="center" rowspan="1" colspan="1">110.29 (96.66, 125.54)</td><td align="center" rowspan="1" colspan="1">399&#160;044 (344&#160;242, 493&#160;758)</td><td align="center" rowspan="1" colspan="1">32.94 (28.47, 40.79)</td></tr><tr><td align="left" rowspan="1" colspan="1">DALYs</td><td align="center" rowspan="1" colspan="1">26&#160;439&#160;968 (23&#160;781&#160;895, 29&#160;256&#160;577)</td><td align="center" rowspan="1" colspan="1">3910.27 (3490.87, 4366.49)</td><td align="center" rowspan="1" colspan="1">15&#160;057&#160;801 (13&#160;108&#160;012, 18&#160;233&#160;001)</td><td align="center" rowspan="1" colspan="1">1119.71 (977.01, 1355.66)</td></tr><tr><td rowspan="4" align="left" colspan="1">South Africa</td><td align="left" rowspan="1" colspan="1">Incidence</td><td align="center" rowspan="1" colspan="1">201&#160;340 (176&#160;410, 225&#160;850)</td><td align="center" rowspan="1" colspan="1">561.56 (500.16, 625.1)</td><td align="center" rowspan="1" colspan="1">271&#160;242 (237&#160;371, 310&#160;915)</td><td align="center" rowspan="1" colspan="1">458.05 (403.15, 517.17)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence</td><td align="center" rowspan="1" colspan="1">17&#160;061&#160;022 (15&#160;315&#160;928, 18&#160;660&#160;471)</td><td align="center" rowspan="1" colspan="1">46979.3 (42773.02, 50732.69)</td><td align="center" rowspan="1" colspan="1">25&#160;212&#160;356 (23&#160;045&#160;234, 27&#160;640&#160;333)</td><td align="center" rowspan="1" colspan="1">44165.9 (40517.48, 48272.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Deaths</td><td align="center" rowspan="1" colspan="1">20&#160;649 (17&#160;508, 25&#160;711)</td><td align="center" rowspan="1" colspan="1">73.33 (61.4, 91.83)</td><td align="center" rowspan="1" colspan="1">22&#160;958 (20&#160;546, 26&#160;533)</td><td align="center" rowspan="1" colspan="1">45.88 (41.06, 52.78)</td></tr><tr><td align="left" rowspan="1" colspan="1">DALYs</td><td align="center" rowspan="1" colspan="1">1&#160;156&#160;855 (998&#160;525, 1&#160;404&#160;265)</td><td align="center" rowspan="1" colspan="1">3420.54 (2935.5, 4192.02)</td><td align="center" rowspan="1" colspan="1">1&#160;029&#160;770 (922&#160;549, 1&#160;174&#160;218)</td><td align="center" rowspan="1" colspan="1">1855.04 (1661.27, 2115.3)</td></tr><tr><td rowspan="4" align="left" colspan="1">Russian Federation</td><td align="left" rowspan="1" colspan="1">Incidence</td><td align="center" rowspan="1" colspan="1">185&#160;620 (160&#160;109, 216&#160;713)</td><td align="center" rowspan="1" colspan="1">114.86 (99.48, 134.33)</td><td align="center" rowspan="1" colspan="1">100&#160;152 (83&#160;637, 122&#160;296)</td><td align="center" rowspan="1" colspan="1">61.11 (51.13, 74.89)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalence</td><td align="center" rowspan="1" colspan="1">50&#160;734&#160;045 (45&#160;516&#160;222, 56&#160;439&#160;587)</td><td align="center" rowspan="1" colspan="1">31996.48 (28795.64, 35616.45)</td><td align="center" rowspan="1" colspan="1">25&#160;587&#160;230 (22&#160;340&#160;839, 29&#160;219&#160;029)</td><td align="center" rowspan="1" colspan="1">15640.9 (13840.02, 17752.85)</td></tr><tr><td align="left" rowspan="1" colspan="1">Deaths</td><td align="center" rowspan="1" colspan="1">10&#160;603 (10&#160;424, 10&#160;773)</td><td align="center" rowspan="1" colspan="1">6.08 (5.98, 6.18)</td><td align="center" rowspan="1" colspan="1">5538 (5061, 5983)</td><td align="center" rowspan="1" colspan="1">2.81 (2.58, 3.03)</td></tr><tr><td align="left" rowspan="1" colspan="1">DALYs</td><td align="center" rowspan="1" colspan="1">457&#160;638 (439&#160;376, 476&#160;944)</td><td align="center" rowspan="1" colspan="1">274.1 (263, 286.14)</td><td align="center" rowspan="1" colspan="1">230&#160;972 (212&#160;476, 250&#160;300)</td><td align="center" rowspan="1" colspan="1">128.7 (118.65, 138.75)</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>DALYs, disability-adjusted life years; UI, uncertainty interval.</p></fn></table-wrap-foot></table-wrap>
<table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>The AAPC in ASIR of tuberculosis from 1990 to 2021</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Location</th><th rowspan="2" align="left" colspan="1">AAPC</th><th colspan="2" align="center" rowspan="1">95% CI</th><th rowspan="2" align="center" colspan="1"><italic toggle="yes">t</italic></th><th rowspan="2" align="center" colspan="1"><italic toggle="yes">P</italic></th></tr><tr><th align="left" rowspan="1" colspan="1">Lower</th><th align="left" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">&#8722;3.491</td><td align="left" rowspan="1" colspan="1">&#8722;3.609</td><td align="left" rowspan="1" colspan="1">&#8722;3.372</td><td align="left" rowspan="1" colspan="1">&#8722;56.638</td><td align="center" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">&#8722;1.997</td><td align="left" rowspan="1" colspan="1">&#8722;2.022</td><td align="left" rowspan="1" colspan="1">&#8722;1.973</td><td align="left" rowspan="1" colspan="1">&#8722;157.427</td><td align="center" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">India</td><td align="left" rowspan="1" colspan="1">&#8722;1.951</td><td align="left" rowspan="1" colspan="1">&#8722;2.040</td><td align="left" rowspan="1" colspan="1">&#8722;1.863</td><td align="left" rowspan="1" colspan="1">&#8722;42.816</td><td align="center" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">South Africa</td><td align="left" rowspan="1" colspan="1">&#8722;0.639</td><td align="left" rowspan="1" colspan="1">&#8722;0.740</td><td align="left" rowspan="1" colspan="1">&#8722;0.538</td><td align="left" rowspan="1" colspan="1">&#8722;12.336</td><td align="center" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Russian Federation</td><td align="left" rowspan="1" colspan="1">&#8722;1.956</td><td align="left" rowspan="1" colspan="1">&#8722;2.436</td><td align="left" rowspan="1" colspan="1">&#8722;1.474</td><td align="left" rowspan="1" colspan="1">&#8722;7.895</td><td align="center" rowspan="1" colspan="1">0.000</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>ASIR, age-standardized incidence rate; AAPC, average annual percent change; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec sec-type="methods"><title>Methods</title><sec sec-type="intro"><title>GBD 2021 overview</title><p>Covering 204 countries, territories, and 811 subnational locations from 1990 to 2021, the GBD study is managed by the Institute for Health Metrics and Evaluation at the University of Washington, which regularly updates the results of the global burden of disease research since 1990 on its website<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup>. The GBD regularly updated the health metrics, particularly including the population forecasts up to the year 2100<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup>.</p><p>And the GBD study employs the disability-adjusted life years (DALYs) as the primary health metric to assess both years of life lost (YLLs) due to premature mortality quantify and years lived with disability<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup>. DALYs represent health loss from fatal and nonfatal outcomes, encompassing the sum of YLLs and years lived with disability<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup>. Metrics were also analyzed in association with Socio-demographic Index (SDI), a composite indicator that typically includes factors such as per capita income, average educational attainment, and total fertility rate within a specific population.</p></sec><sec><title>Disease definition</title><p>TB remains a major contributor to morbidity and mortality globally, caused by <italic toggle="yes">M. tuberculosis</italic> as an infectious bacterial disease<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup>. In GBD, a hierarchical system is often employed to divide the causes into four levels, ranging from the most extensive (Level 1; e.g. communicable, maternal, neonatal, and nutritional diseases), to the most specific (Level 4; e.g. lower respiratory infections). TB, being a part of respiratory infections and TB, is classified as a Level 3 cause. The subtypes of TB are further broken down and are considered Level 4 causes.</p><p>In the present study, we report estimates for DS-TB, MDR-TB, and XDR-TB. DS-TB is characterized by susceptibility to the first-line drugs isoniazid and rifampicin. MDR-TB is characterized by resistance to rifampicin and isoniazid yet remains sensitive to any fluoroquinolone and second-line injectable drug. XDR-TB is characterized by resistance to rifampicin, isoniazid, any fluoroquinolone, and at least one second-line injectable drug<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup>.</p></sec><sec><title>Data source</title><p>The latest data utilized in the research were sourced from GBD 2021, available via the Global Health Data Exchange online platform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://vizhub.healthdata.org/gbd-results/" ext-link-type="uri">https://vizhub.healthdata.org/gbd-results/</ext-link>). Employing the GBD 2021 dataset, we described and estimated the trends in TB burden in BRICS using four standard epidemiological measures: incidence, prevalence, death, and DALYs, along with their corresponding age-standardized rates (ASR) between 1990 and 2021. The crude and age-standardized estimates, as well as the corresponding 95% uncertainty intervals (UI) were gathered. All measures extracted from GBD were stratified by age, sex, and three subtypes of TB (MDR-TB, XDR-TB, DS-TB) over the period from 1990 to 2021.</p><p>Furthermore, based on five SDI quintiles, we collected data to investigate the disparities in disease burden across regions with high, high-middle, middle, low-middle, and low SDI levels. Our study also focused on risk factors contributing to TB mortality and DALYs including three key risk factors (smoking, high alcohol use, and high fasting plasma glucose [HFPG]) provided by the GBD study. Prior studies have elucidated the hierarchy of risk factors and provided detailed definitions of exposure<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup>.</p></sec><sec><title>Statistical analysis</title><p>First, to elucidate the extent and directionality of temporal trends, the joinpoint regression analysis was used to determine the average annual percent change (AAPC) and 95% CI for four metrics: ASIR, ASPR, ASMR, and ASDR from 1990 to 2021. When AAPC &gt;0 and the <italic toggle="yes">P</italic>-value &lt;0.05, it indicates a statistically significant increasing trend in ASR over the study duration; when AAPC &lt;0 and <italic toggle="yes">P</italic>-value &lt;0.05, it shows a decreasing trend in the ASR; when <italic toggle="yes">P</italic> &#8805; 0.05, it suggests no significant change in the rate. Finally, a Bayesian age-period-cohort (BAPC) analysis was executed using BAPC and INLA packages in R.</p><p>We utilized joinpoint software (v5.1.0, Statistical Research and Applications Branch, National Cancer Institute, USA) to carry out joinpoint regression analysis. And the statistical analysis and data visualization were performed with R software (version 4.4.1). A two-tailed <italic toggle="yes">P</italic>-value less than 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Description of the burden of TB globally and in BRICS countries</title><sec><title>Incidence of TB</title><p>Globally, while the incident cases of TB showed a slight decrease from 8 598 520 (95% UI: 7 528 228&#8211;9 854 794) in 1990 to 8 407 133 (7 519 793&#8211;9 393 767) in 2021, the ASIR fell from 170.03 (152.88&#8211;198.71) to 103 (92.21&#8211;114.91) per 100 000 population. Conversely, despite an increase in the total number of TB incidence cases over the same period in India and South Africa, these countries experienced significant declines in ASIRs, highlighting progress in disease control despite the rise in overall cases.</p></sec><sec><title>Prevalence of TB</title><p>China had high prevalence of TB cases in both 1990 and 2021, respectively accounting for about 23.03% and 25.71% of the global total. Compared to 1990, the most significant reductions in ASPR of TB were observed in Brazil (35.34%) and the Russian Federation (51.12%) in 2021, resulting in a relatively reduced burden of TB.</p></sec><sec><title>Mortality of TB</title><p>On a global scale, significant reductions have been observed in both the total mortality number and the ASMR. Nations such as China, Brazil, India, and the Russian Federation have each noted considerable declines. Conversely, South Africa has witnessed an increase in overall mortality, whereas the ASMR has notably decreased.</p></sec><sec><title>DALYs of TB</title><p>From 1990 to 2021, the DALYs of global and the BRICS have all decreased, with China experiencing the steepest decline of 81.22% (from 7 325 730 to 1 375 510), while South Africa had the smallest reduction rate of only 10.99% (from 1 156 855 to 1 029 770). A consistent decline in ASDR was observed from 1990 to 2021.</p><p>Overall, the results of these measures showed that India ranks first among the BRICS, followed by China.</p></sec><sec><title>Trends of TB from 1990 to 2021</title><p>The joinpoint regression analysis indicated a generally significant downward trend in the ASRs of TB among BRICS countries from 1990 to 2021 (Fig. <xref rid="F1" ref-type="fig">1</xref>).<fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>A comprehensive view depicting the structure of the literature.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6050-g001.jpg"/><attrib>SDI, Socio-demographic Index; DALYs, disability-adjusted life years; ASR, age-standardized rate; DS-TB, drug-susceptible tuberculosis; MDR-TB, multidrug-resistant without extensive drug resistance tuberculosis; XDR-TB, extensively drug resistance tuberculosis; APC, annual percentage change; AAPC, average annual percent change; ASPR, age-standardized prevalence rate; ASDR, age-standardized DALY rate.</attrib></fig>
<fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Trends of the age-standardized rates (ASRs) for tuberculosis from 1990 to 2021. (A) Age-standardized incidence rate (ASIR). (B) Age-standardized prevalence rate (ASPR). (C) Age-standardized mortality rate (ASMR). (D) Age-standardized DALYs rate (ASDR).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6050-g002.jpg"/><attrib>ASRs, age-standardized rates; ASIR, age-standardized incidence rate; ASPR, age-standardized prevalence rate; ASMR, age-standardized mortality rate; ASDR, age-standardized DALYs rate.</attrib></fig>
</p><p>A notable decline of ASIR was observed in India compared to the other BRICS countries (Fig. <xref rid="F1" ref-type="fig">1</xref>A). In the Russian Federation, the trend increased first from 1990 to 2003, and then decreased thereafter until 2021. Meanwhile, the analysis revealed a notable downward trajectory in the ASPR of TB, exhibiting a consistent pattern across both Brazil and the Russian Federation (Fig. <xref rid="F1" ref-type="fig">1</xref>B and Supplemental Digital Content Table 1, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E446" ext-link-type="uri">http://links.lww.com/JS9/E446</ext-link>). The trend observed in the ASDR plots is similar to that observed in the ASMR data (Fig. <xref rid="F1" ref-type="fig">1</xref>D).</p></sec><sec><title>Age-specific burden of TB in 1990 and 2021</title><p>The incidence and mortality rates generally increased with advancing age groups up to the oldest age group (&#8805;95&#160;years) basically across the BRICS. Interestingly, patterns in burden by age were similar across years from 1990 to 2021 for India and the Russian Federation. Compared to other countries, South Africa and India exhibited higher incidence rates across all age groups in 1990 and 2021 (Fig. <xref rid="F3" ref-type="fig">3</xref>A and B). The rate of prevalence was highest in South Africa in both 1990 and 2021 across all age groups among the BRICS (Fig. <xref rid="F3" ref-type="fig">3</xref>C and D). Moreover, it&#8217;s remarkable that the peak prevalence rates in China, Brazil, India, and the Russian Federation were all observed at 45&#8211;69&#160;years in 2021 generally. In contrast to Brazil and the Russian Federation, whose mortality rates exhibited minimal fluctuation, India demonstrated persistently elevated mortality rates among older age groups, peaking in the 80&#8211;84 and 90&#8211;94 age groups in both years (Fig. <xref rid="F4" ref-type="fig">4</xref>).<fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Average annual percentage change (AAPC) analysis of tuberculosis across BRICS countries from 1990 to 2021. (A) ASIR, (B) ASPR, (C) ASMR, (D) ASDR.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6050-g003.jpg"/><attrib>AAPC, average annual percentage change; ASIR, age-standardized incidence rate; ASPR, age-standardized prevalence rate; ASMR, age-standardized mortality rate; ASDR, age-standardized DALYs rate; CI, confidential interval.</attrib></fig>
<fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>Tuberculosis age distribution of ASR in BRICS countries in 1990 and 2021. (A) ASIR in 1990, (B) ASIR in 2021, (C) ASPR in 1990, (D) ASPR in 2021.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6050-g004.jpg"/><attrib>ASR, age-standardized rate; ASIR, age-standardized incidence rate; ASPR, age-standardized prevalence rate.</attrib></fig>
<fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p>Tuberculosis age distribution of ASR in BRICS countries in 1990 and 2021. (A) ASMR in 1990, (B) ASMR in 2021, (C) ASDR in 1990, (D) ASDR in 2021.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6050-g005.jpg"/><attrib>ASR, age-standardized rate; ASMR, age-standardized mortality rate; ASDR, age-standardized DALYs rate.</attrib></fig>
<fig position="float" id="F6" orientation="portrait"><label>Figure 6.</label><caption><p>All-age crude deaths and DALYs of tuberculosis by cause category in 1990 and 2021. (A) Crude deaths, (B) crude DALYs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6050-g006.jpg"/><attrib>DALYs, disability-adjusted life years; DS-TB, drug-susceptible tuberculosis; MDR-TB, multidrug-resistant without extensive drug resistance tuberculosis; XDR-TB, extensively drug resistance tuberculosis.</attrib></fig>
</p></sec><sec><title>Cause-specific burden of TB in 1990 and 2021</title><p>We found that DS-TB resulted in substantially more total deaths and DALYs than MDR-TB and XDR-TB in 1990 and 2021 across the BRICS and different SDI regions. The most striking increases were observed in the Russian Federation, where the XDR-TB mortality rate reached 14.5%, and in high SDI regions, where the rate was 4.5%. It&#8217;s worth noting that the MDR-TB mortality rate in the Russian Federation has reached 31.1% in 2021, an increase of 12 times from the 2.4% in 1990.</p></sec></sec></sec><sec><title>Risk factors</title><sec><title>Ranking of the contribution of risk factors to the TB burden</title><p>Figure <xref rid="F7" ref-type="fig">7</xref> reveals that the ranking of TB disease burden caused by various risk factors has remained basically unchanged except for HFPG in 2021 compared to 1990. The top five most significant risk factors at the most granular level globally were ranked as follows: smoking, high alcohol use, HFPG, high body mass index, and low physical activity.<fig position="float" id="F7" orientation="portrait"><label>Figure 7.</label><caption><p>Risk factors ranked globally for deaths (A) and DALYs (B) for 1990 and 2021, with mean change of counts and age-standardized deaths and DALYs rate.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6050-g007.jpg"/><attrib>SDI, Socio-demographic Index; ASMR, age-standardized mortality rate; ASDR, age-standardized DALYs rate; DALYs, disability-adjusted life years.</attrib></fig>
</p></sec><sec><title>TB mortality and DALYs attributable to individual risk factors</title><sec><title>BRICS countries level</title><p>The contribution of smoking to the deaths in China and the Russian Federation indicated that the risk was significantly higher than in other BRICS countries in both 1990 and 2021. Strikingly, the percentage for TB mortality due to smoking, which ranked as the second risk factors in males, was over four times higher than females in 1990 and 2021. It is worth noting that compared to 1990, both men and women were more likely to have a greater burden of TB due to HFPG in 2021.</p><p>Compared to 1990, there was a general trend for males to have a higher proportion of the three risk factors than females, especially in China and the Russian Federation in 2021.</p></sec><sec><title>SDI regions level</title><p>The proportion of deaths for both sexes attributable to HFPG rose gradually with increasing SDI in 1990, slightly different from 2021. What deserves attention is that between 1990 and 2021, the percentage of smoking-attributable deaths and DALYs was higher for males compared to females in all SDI regions and BRICS countries. In conclusion, for these three risk factors, males bear a heavier burden of TB disease.</p></sec><sec><title>Future forecasts of the burden of disease in TB</title><p>Generally, there was an observed overall downward trend in both ASIR and ASMR across BRICS countries. The ASIR for both males and females was projected to decline gradually, with estimates indicating approximately 96 and 73 per 100 000 population in 2035 globally. Significant declines of ASIR and ASMR were observed by different sexes in the Russian Federation and China, a pattern expected to continue through 2036 (Figs. <xref rid="F8" ref-type="fig">8</xref> and <xref rid="F9" ref-type="fig">9</xref>). According to the projection, the ASPR and ASDR were predicted to decrease in the coming years (Supplemental Digital Content Figures 1, 3, 6, 7, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E446" ext-link-type="uri">http://links.lww.com/JS9/E446</ext-link>).<fig position="float" id="F8" orientation="portrait"><label>Figure 8.</label><caption><p>Proportion of tuberculosis deaths and DALYs attributable to smoking and high alcohol use, high fasting plasma in 1990 and 2021. (A) Proportion of tuberculosis deaths in 1990. (B) Proportion of tuberculosis DALYs in 1990. (C) Proportion of tuberculosis deaths in 2021. (D) Proportion of tuberculosis DALYs in 2021.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6050-g008.jpg"/><attrib>SDI, Socio-demographic Index; DALYs, disability-adjusted life years.</attrib></fig>
<fig position="float" id="F9" orientation="portrait"><label>Figure 9.</label><caption><p>Trends in tuberculosis ASIR from 2021 to 2036 in female. (A) Brazil, (B) China, (C) India, (D) Russian Federation, (E) South Africa, (F) Global.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6050-g009.jpg"/><attrib>ASIR, age-standardized incidence rate; BAPC, Bayesian age-period-cohort.</attrib></fig>
</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Over the last three decades, although the declines of incidence and death cases were all observed globally, it indicated that the first End TB Strategy was far from being realized until 2021<sup>[<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref>]</sup>. According to the report, BRICS are among the countries with the highest burden of TB. They account for 46% of all new TB cases and 40% of all TB-related mortality<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup>. Our findings revealed a general downward trend in ASR across these five countries from 1990 to 2021. This decline may be attributed to the significant increase in per capita health expenditure observed in Brazil, China, South Africa, and India following the establishment of BRICS countries in 2006. Between 1995 and 1997, the World Bank adopted Directly Observed Treatment Short-course (DOTS) as its primary strategy for TB control. Notably, World Bank funding and development assistance for TB control was primarily concentrated in South Asia and Africa, with India and China being the foremost recipients of such commitments from 1986 to 2017<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup>. Among them, India achieved 100% DOTS coverage in 2006 by revising its National Tuberculosis Control Program (RNTCP)<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup>. Undoubtedly, these are some of the contributing factors to the decline in TB incidence during this period. Research indicated that a direct correlation was observed between the economic downturn of the 1990s and the exacerbation of the TB epidemic in the Russian Federation<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup>. The economic crisis contributed to a surge in the TB incidence rate, reaching its peak during this period. Interestingly, our findings further revealed that the Russian Federation experienced even more substantial declines in TB cases after the BRICS founded. From 2000 to 2010, the government implemented stringent measures to curb the spread of TB, also resulting in a decline in cases.</p><p>Based on their political commitment, resource allocation, and multifaceted collaboration, BRICS countries have achieved remarkable progress in the prevention, control, and treatment of TB. They have deepened their cooperation and made significant contributions in multiple related fields, such as diagnostic tests, vaccines, and novel drug therapies, demonstrating their commitment to advancing the fight against TB and embodying the rationality of policymaking and research input<sup>[<xref rid="R23" ref-type="bibr">23</xref>&#8211;<xref rid="R25" ref-type="bibr">25</xref>]</sup>. Specifically, BRICS countries have allocated substantial domestic funding to TB care, which has had a marked effect on improving access to high-quality services for vulnerable populations<sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup>. For instance, the Russian Federation invested over a billion United States dollars annually in TB care<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup>.</p><p>Furthermore, we conducted a group-based investigation in BRICS countries. Our findings revealed that the incidence rates generally rise with advancing age groups in the BRICS. Similarly, a study also ascertained an augmented incidence of TB in individuals aged over 65&#160;years<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup>. Although the relative contribution of aging varied across BRICS countries, it is an important risk factor for developing TB, with inflammation being recognized as a key contributing element<sup>[<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>]</sup>. Moreover, elderly individuals face other numerous challenges, including diminished lung function, immune-senescence, adverse drug effects, poor tolerance to anti-TB medications, as well as the presence of age-related comorbidities<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup>. Individuals over 60&#160;years old in India and South Africa continue to exhibit higher mortality rates relative to other nations. As previously mentioned, some individuals are infected with <italic toggle="yes">M. tuberculosis</italic> without showing clinical symptoms. With the decline in immune function that comes with aging, dormant lesions are more likely to reactivate, contributing to a higher mortality rate from pulmonary TB in elderly patients<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup>. To tackle the increasingly heavy TB burden in the elderly population, it is critical to strengthen the screening of high-risk groups and optimize treatment regimens for elderly patients. For instance, early detection can be achieved through tuberculin skin test and interferon-gamma release assays<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup>. Dosing of anti-TB drugs should be individualized based on liver and kidney function to mitigate the incidence of adverse drug reactions, while strengthening comprehensive chronic disease management for TB remains imperative.</p><p>The Russian Federation experienced a notably high burden of drug-resistant TB, with approximately 30% of deaths and 14% of DALYs attributed to MDR-TB and XDR-TB, respectively in 2021. Drug-resistant TB is not merely a regional concern but has escalated into a global challenge, significantly impacting public health. In contrast to DS-TB, patients with MDR-TB or XDR-TB must require a treatment regimen consisting of more than seven drugs over a longer duration<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup>. This treatment regimen is associated with a high failure rate and significant drug toxicity. Moreover, approximately 50% of MDR and XDR pulmonary TB patients remain uncured. These individuals continue to spread the disease. The financial burden is substantial: although cases of MDR-TB represent less than 5%&#8211;10% of the total TB burden, they often consume over 50% of the national TB budget<sup>[<xref rid="R34" ref-type="bibr">34</xref>]</sup>. Based on DOTS, DOTS-Plus incorporates second-line anti-TB drugs, extends treatment duration, and emphasizes personalized treatment tailored to patients, aiming to boost treatment success rates, particularly in high-drug-resistance regions. This strategy is particularly applicable to low-and middle-income countries and regions with limited resources<sup>[<xref rid="R35" ref-type="bibr">35</xref>]</sup>. Even though the WHO proposed the DOTS-Plus strategy in 1998, our results show that, compared with 1990, the proportion of MDR-TB in BRICS countries was still increasing in 2021. Therefore, in response to the continuously rising proportion of MDR-TB, it is imperative to popularize the GeneXpert rapid molecular diagnostic technology in primary healthcare facilities. Meanwhile, BRICS countries should strengthen their drug-resistance detection networks, promote international collaboration, and advance the development of vaccines and new drugs.</p><p>Globally, TB is concentrated in low- to middle-income countries. Indeed, studies have suggested that the prevalence of TB depends on the socioeconomic development status and social protection measures<sup>[<xref rid="R36" ref-type="bibr">36</xref>]</sup>. It&#8217;s worth noting that the COVID-19 pandemic has a catastrophic influence in society and economy, leading to the rising of poverty, which is a crucial driving factor to TB pandemic<sup>[<xref rid="R37" ref-type="bibr">37</xref>]</sup>. Factors contributing to the transmission of TB include limited access to healthcare, poor nutrition, and substandard living conditions, etc<sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup>. Consequently, implementation targeting socioeconomic interventions that fight poverty is pivotal in tackling the high burden of TB.</p><p>Our study confirmed previous findings<sup>[<xref rid="R39" ref-type="bibr">39</xref>&#8211;<xref rid="R41" ref-type="bibr">41</xref>]</sup>, indicating that high alcohol use, HFPG and smoking behavior may elevate the risk of TB in BRICS. The estimates revealed the evident sex differences in the deaths and DALYs due to smoking. In fact, data suggested that males exhibit a higher susceptibility to active pulmonary diseases compared to females<sup>[<xref rid="R42" ref-type="bibr">42</xref>]</sup>. The elevated TB burden in males is significantly impacted by non-biological factors, notably smoking. Increased attention is also being devoted to the impacts of biological factors on TB. The BRICS countries are experiencing rapid economic expansion and exhibit marked trends toward urbanization and globalization. This is accompanied by a progressively increasing risk of disease burden attributed to chronic diseases, such as diabetes<sup>[<xref rid="R43" ref-type="bibr">43</xref>]</sup>. As showed in other research, HFPG, one of the diagnostic criteria for diabetes, impacts the disease burden of other diseases, including TB<sup>[<xref rid="R44" ref-type="bibr">44</xref>]</sup>. In a comparison between 1990 and 2021, we found that high fasting plasma glucose (HFPR) accounted for larger proportion of deaths and DALYs in BRICS countries. A cohort study indicates that TB patients with HFPG exhibit intensified clinical symptoms, lung involvement and higher bacterial burden<sup>[<xref rid="R45" ref-type="bibr">45</xref>]</sup>. Impaired blood glucose management not only compromises treatment outcomes for TB but also correlates with increased mortality rates<sup>[<xref rid="R46" ref-type="bibr">46</xref>]</sup>. Focusing on carrying out innovative strategies to address the heavy burden of HFPR might be beneficial to TB control programs. In conclusion, regarding the higher TB burden due to smoking and alcohol consumption, BRICS countries should enforce stricter policies on tobacco and alcohol control, conduct community-based monitoring of smoking and alcohol use, and intensify health education initiatives. Metabolic diseases such as diabetes should be integrated into the TB prevention and control system. For example, blood glucose levels should be simultaneously tested during TB screenings.</p><p>Based on the WHO&#8217;s End TB Strategy 2035 milestones, we predicted the ASIR and ASMR by 2035. There has been a decline across BRICS countries, particularly with notable reductions in the Russian Federation and China. From 2015 to 2035, the global reduction in ASIR among females was 27%, and the ASMR was 51%. Despite these encouraging decreases, it is imperative that BRICS countries intensify their efforts to achieve the 2035 goal of reducing mortality by 95% and incidence rates by 90%, to less than 10 cases per 100 000 population, ultimately aiming to end the TB epidemic. The predicted rates in South Africa and India were significantly higher than their counterparts. South Africa faces barriers such as the frequent occurrence of medicine stockouts, HIV infection, drug-resistant TB, etc<sup>[<xref rid="R47" ref-type="bibr">47</xref>,<xref rid="R48" ref-type="bibr">48</xref>]</sup>. The severe TB burden in India may be attributed to a series of barriers, including inadequate funding, poor diagnostic facilities, under-reporting, and low treatment success rates. To address these issues, measures such as strengthening the health system, upgrading diagnostic capabilities, incorporating the latest diagnostic technologies, and advocating for increased budgetary support are essential for leading India closer to a TB-free future<sup>[<xref rid="R49" ref-type="bibr">49</xref>]</sup>.</p><p>The GBD results may contain inaccuracies owing to the lack of actual observational data. Furthermore, the failure to collect data from certain low-income countries or remote regions poses a risk of underestimating the actual burden of TB. Lastly, the inability to obtain precise exposure information in epidemiological studies prevents the quantification of associated risks.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Over the past three decades, the descending trend of TB burden has been observed, which is expected to keep on in the future. Nowadays, setting policies and tailoring educational interventions are very crucial to reduce the impact of risk factors on the burden of TB. Ultimately, this research could provide valuable insights for TB prevention and control, guiding the allocation of healthcare resources in response to the varying conditions across BRICS countries.</p></sec></body><back><ack><title>Acknowledgements</title><p>We appreciate the excellent works by the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 collaborators.</p></ack><fn-group><fn fn-type="other"><p>X.Z. and M.G. authors contributed to the work equally and should be regarded as co-first authors.</p></fn><fn fn-type="other"><p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p></fn><fn fn-type="other"><p>Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal&#8217;s website, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.lww.com/international-journal-of-surgery" ext-link-type="uri">www.lww.com/international-journal-of-surgery</ext-link>.</p></fn><fn fn-type="equal"><p>Published online 20 June 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>Not applicable.</p></sec><sec><title>Consent</title><p>Not applicable.</p></sec><sec><title>Sources of funding</title><p>This study was supported by Inner Mongolia Academy of Medical Sciences public hospital research joint fund project (No. 2024GLLH0255).</p></sec><sec><title>Author contributions</title><p>Investigation, visualization, and writing &#8211; original draft: X.M.Z.; methodology, formal analysis, and writing &#8211; original draft: M.R.G.; funding acquisition and conceptualization: X.F.S.; writing &#8211; review &amp; editing: A.E.A.; project administration, supervision, and validation: G.R.W. and L.X.X. All authors have read and agreed to the published version of the manuscript</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>Not applicable.</p></sec><sec><title>Guarantor</title><p>Xiaomeng Zhang and Abualgasim Elgaili Abdalla.</p></sec><sec><title>Provenance and peer review</title><p>Not commissioned, externally peer reviewed.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>The data utilized in this study could be accessed openly through GBD 2021 online database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ghdx.healthdata.org/gbd-results-tool" ext-link-type="uri">http://ghdx.healthdata.org/gbd-results-tool</ext-link>), as described in the Methods section.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boom</surname><given-names>WH</given-names></name><name name-style="western"><surname>Schaible</surname><given-names>UE</given-names></name><name name-style="western"><surname>Achkar</surname><given-names>JM</given-names></name></person-group>. <article-title>The knowns and unknowns of latent <italic toggle="yes">Mycobacterium tuberculosis</italic> infection</article-title>. <source>J Clin Invest</source><year>2021</year>;<volume>131</volume>:<fpage>e136222</fpage>.<pub-id pub-id-type="pmid">33529162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI136222</pub-id><pub-id pub-id-type="pmcid">PMC7843221</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="book"><article-title>Global Tuberculosis Report 2024</article-title>. <publisher-name>World Health Organization</publisher-name>; <year>2024</year>.</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seung</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Keshavjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Rich</surname><given-names>ML</given-names></name></person-group>. <article-title>Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis</article-title>. <source>Cold Spring Harb Perspect Med</source><year>2015</year>;<volume>5</volume>:<fpage>a017863</fpage>.<pub-id pub-id-type="pmid">25918181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a017863</pub-id><pub-id pub-id-type="pmcid">PMC4561400</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Floyd</surname><given-names>K</given-names></name><name name-style="western"><surname>Glaziou</surname><given-names>P</given-names></name><name name-style="western"><surname>Houben</surname><given-names>R</given-names></name><name name-style="western"><surname>Sumner</surname><given-names>T</given-names></name><name name-style="western"><surname>White</surname><given-names>RG</given-names></name><name name-style="western"><surname>Raviglione</surname><given-names>M</given-names></name></person-group>. <article-title>Global tuberculosis targets and milestones set for 2016-2035: definition and rationale</article-title>. <source>Int J Tuberc Lung Dis</source><year>2018</year>;<volume>22</volume>:<fpage>723</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">29914597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5588/ijtld.17.0835</pub-id><pub-id pub-id-type="pmcid">PMC6005124</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Creswell</surname><given-names>J</given-names></name><name name-style="western"><surname>Sahu</surname><given-names>S</given-names></name><name name-style="western"><surname>Sachdeva</surname><given-names>KS</given-names></name><etal/></person-group>. <article-title>Tuberculosis in BRICS: challenges and opportunities for leadership within the post-2015 agenda</article-title>. <source>Bull World Health Organ</source><year>2014</year>;<volume>92</volume>:<fpage>459</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">24940023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2471/BLT.13.133116</pub-id><pub-id pub-id-type="pmcid">PMC4047808</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>de Macedo Couto</surname><given-names>R</given-names></name><name name-style="western"><surname>Pelissari</surname><given-names>DM</given-names></name><etal/></person-group>. <article-title>Excess tuberculosis cases and deaths following an economic recession in Brazil: an analysis of nationally representative disease registry data</article-title>. <source>Lancet Glob Health</source><year>2022</year>;<volume>10</volume>:<fpage>e1463</fpage>&#8211;<lpage>e72</lpage>.<pub-id pub-id-type="pmid">36049488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(22)00320-5</pub-id><pub-id pub-id-type="pmcid">PMC9472578</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dania</surname><given-names>E</given-names></name><name name-style="western"><surname>Stiegler</surname><given-names>N</given-names></name><name name-style="western"><surname>Bouchard</surname><given-names>JP</given-names></name></person-group>. <article-title>Tuberculosis remains a public health issue in South Africa</article-title>. <source>La Revue de l&#8217;Infirmi&#232;re</source><year>2023</year>;<volume>72</volume>:<fpage>39</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.revinf.2023.03.010</pub-id><pub-id pub-id-type="pmid">37088495</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="book"><collab>Institute of M</collab>. <source>The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences</source>. <person-group person-group-type="editor"><name name-style="western"><surname>Steve</surname><given-names>O</given-names></name><name name-style="western"><surname>Rebecca</surname><given-names>AE</given-names></name><name name-style="western"><surname>Anne</surname><given-names>BC</given-names></name></person-group>, editors. <publisher-name>The National Academies Press</publisher-name>; <year>2014</year>.<pub-id pub-id-type="pmid">24404635</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Hay</surname><given-names>SI</given-names></name><etal/></person-group>. <article-title>Time trends in tuberculosis mortality across the BRICS: an age-period-cohort analysis for the GBD 2019</article-title>. <source>EClinicalMedicine</source><year>2022</year>;<volume>53</volume>:<fpage>101646</fpage>.<pub-id pub-id-type="pmid">36147625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2022.101646</pub-id><pub-id pub-id-type="pmcid">PMC9486016</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Jing</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name></person-group>. <article-title>Health disparity and mortality trends of infectious diseases in BRICS from 1990 to 2019</article-title>. <source>J Glob Health</source><year>2022</year>;<volume>12</volume>:<fpage>04028</fpage>.<pub-id pub-id-type="pmid">35356649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7189/jogh.12.04028</pub-id><pub-id pub-id-type="pmcid">PMC8943566</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agha RA</surname><given-names>MG</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>R</given-names></name><name name-style="western"><surname>Kerwan</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Transparency In The Reporting of Artificial INtelligence &#8211; the TITAN guideline</article-title>. <source>Premier Journal of Science</source><year>2025</year>;<volume>10</volume>:<fpage>100082</fpage>.</mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diseases</surname><given-names>GBD</given-names></name><name name-style="western"><surname>Injuries</surname><given-names>C</given-names></name></person-group>. <article-title>Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021</article-title>. <source>Lancet</source><year>2024</year>;<volume>403</volume>:<fpage>2133</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">38642570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(24)00757-8</pub-id><pub-id pub-id-type="pmcid">PMC11122111</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><collab>Collaborators GBDD</collab>. <article-title>Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021</article-title>. <source>Lancet</source><year>2024</year>;<volume>403</volume>:<fpage>1989</fpage>&#8211;<lpage>2056</lpage>.<pub-id pub-id-type="pmid">38484753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(24)00476-8</pub-id><pub-id pub-id-type="pmcid">PMC11126395</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><collab>Disease GBD</collab>. <person-group person-group-type="author"><name name-style="western"><surname>Injury</surname><given-names>I</given-names></name><name name-style="western"><surname>Prevalence</surname><given-names>C</given-names></name></person-group>. <article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title>. <source>Lancet</source><year>2018</year>;<volume>392</volume>:<fpage>1789</fpage>&#8211;<lpage>858</lpage>.<pub-id pub-id-type="pmid">30496104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)32279-7</pub-id><pub-id pub-id-type="pmcid">PMC6227754</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><collab>Collaborators GBDT</collab>. <person-group person-group-type="author"><name name-style="western"><surname>Kyu</surname><given-names>HH</given-names></name><name name-style="western"><surname>Maddison</surname><given-names>ER</given-names></name><name name-style="western"><surname>Henry</surname><given-names>NJ</given-names></name></person-group>. <article-title>Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study</article-title>. <source>Lancet Infect Dis</source><year>2018</year>;<volume>18</volume>:<fpage>1329</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">30507459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(18)30625-X</pub-id><pub-id pub-id-type="pmcid">PMC6250050</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="book"><article-title>Global tuberculosis report 2023</article-title>. <publisher-name>World Health Organization</publisher-name>; <year>2023</year> .</mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><collab>Collaborators GBDRF</collab>. <article-title>Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019</article-title>. <source>Lancet</source><year>2020</year>;<volume>396</volume>:<fpage>1223</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">33069327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30752-2</pub-id><pub-id pub-id-type="pmcid">PMC7566194</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnamoorthy</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nagarajan</surname><given-names>R</given-names></name><name name-style="western"><surname>Rajaa</surname><given-names>S</given-names></name><name name-style="western"><surname>Majella</surname><given-names>MG</given-names></name><name name-style="western"><surname>Murali</surname><given-names>S</given-names></name><name name-style="western"><surname>Jayaseelan</surname><given-names>V</given-names></name></person-group>. <article-title>Progress of South East Asian Region countries towards achieving interim End TB strategy targets for TB incidence and mortality: a modelling study</article-title>. <source>Public Health</source><year>2021</year>;<volume>198</volume>:<fpage>9</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">34340014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.puhe.2021.06.021</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukunaga</surname><given-names>R</given-names></name><name name-style="western"><surname>Glaziou</surname><given-names>P</given-names></name><name name-style="western"><surname>Harris</surname><given-names>JB</given-names></name><name name-style="western"><surname>Date</surname><given-names>A</given-names></name><name name-style="western"><surname>Floyd</surname><given-names>K</given-names></name><name name-style="western"><surname>Kasaeva</surname><given-names>T</given-names></name></person-group>. <article-title>Epidemiology of tuberculosis and progress toward meeting global targets - worldwide, 2019</article-title>. <source>MMWR Morb Mortal Wkly Rep</source><year>2021</year>;<volume>70</volume>:<fpage>427</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">33764960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7012a4</pub-id><pub-id pub-id-type="pmcid">PMC7993552</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahi</surname><given-names>M</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>G</given-names></name><name name-style="western"><surname>Winters</surname><given-names>J</given-names></name><name name-style="western"><surname>Sridhar</surname><given-names>D</given-names></name></person-group>. <article-title>The World Bank &amp; financing tuberculosis control, 1986-2017 [version 1; peer review: 2 approved with reservations]</article-title>. <source>Wellcome Open Res</source><year>2018</year>;<volume>3</volume>:<fpage>103</fpage>.</mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yashodhara</surname><given-names>BM</given-names></name><name name-style="western"><surname>Huat</surname><given-names>CB</given-names></name><name name-style="western"><surname>Naik</surname><given-names>LN</given-names></name><name name-style="western"><surname>Umakanth</surname><given-names>S</given-names></name><name name-style="western"><surname>Hande</surname><given-names>M</given-names></name><name name-style="western"><surname>Pappachan</surname><given-names>JM</given-names></name></person-group>. <article-title>Multidrug and extensively drug-resistant tuberculosis from a general practice perspective</article-title>. <source>Infect Drug Resist</source><year>2010</year>;<volume>3</volume>:<fpage>115</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">21694900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IDR.S10743</pub-id><pub-id pub-id-type="pmcid">PMC3108735</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meshkov</surname><given-names>I</given-names></name><name name-style="western"><surname>Petrenko</surname><given-names>T</given-names></name><name name-style="western"><surname>Keiser</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Variations in tuberculosis prevalence, Russian Federation: a multivariate approach</article-title>. <source>Bull World Health Organ</source><year>2019</year>;<volume>97</volume>:<fpage>737</fpage>&#8211;<lpage>745A</lpage>.<pub-id pub-id-type="pmid">31673189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2471/BLT.19.229997</pub-id><pub-id pub-id-type="pmcid">PMC6802703</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathebula</surname><given-names>L</given-names></name><name name-style="western"><surname>Mapahla</surname><given-names>L</given-names></name><name name-style="western"><surname>Nurkhametova</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Planned, ongoing and completed tuberculosis treatment trials in Brazil, Russia, India, China and South Africa: a 2019 cross-sectional descriptive analysis</article-title>. <source>BMJ Open</source><year>2022</year>;<volume>12</volume>:<fpage>e057941</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2021-057941</pub-id><pub-id pub-id-type="pmcid">PMC9185397</pub-id><pub-id pub-id-type="pmid">35680261</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lienhardt</surname><given-names>C</given-names></name><name name-style="western"><surname>L&#246;nnroth</surname><given-names>K</given-names></name><name name-style="western"><surname>Menzies</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Translational research for tuberculosis elimination: priorities, challenges, and actions</article-title>. <source>PLoS Med</source><year>2016</year>;<volume>13</volume>:<fpage>e1001965</fpage>.<pub-id pub-id-type="pmid">26933883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1001965</pub-id><pub-id pub-id-type="pmcid">PMC4775029</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pai</surname><given-names>M</given-names></name></person-group>. <article-title>Time for high-burden countries to lead the tuberculosis research agenda</article-title>. <source>PLoS Med</source><year>2018</year>;<volume>15</volume>:<fpage>e1002544</fpage>.<pub-id pub-id-type="pmid">29570726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.1002544</pub-id><pub-id pub-id-type="pmcid">PMC5865711</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menzies</surname><given-names>NA</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>GB</given-names></name><name name-style="western"><surname>Bozzani</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models</article-title>. <source>Lancet Glob Health</source><year>2016</year>;<volume>4</volume>:<fpage>e816</fpage>&#8211;<lpage>e26</lpage>.<pub-id pub-id-type="pmid">27720689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(16)30265-0</pub-id><pub-id pub-id-type="pmcid">PMC5527122</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>A long-term trend study of tuberculosis incidence in China, India and United States 1992-2017: a joinpoint and age-period-cohort analysis</article-title>. <source>Int J Environ Res Public Health</source><year>2020</year>;<volume>17</volume>:<fpage>3334</fpage>.<pub-id pub-id-type="pmid">32403353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph17093334</pub-id><pub-id pub-id-type="pmcid">PMC7246898</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piergallini</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Turner</surname><given-names>J</given-names></name></person-group>. <article-title>Tuberculosis in the elderly: why inflammation matters</article-title>. <source>Exp Gerontol</source><year>2018</year>;<volume>105</volume>:<fpage>32</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">29287772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exger.2017.12.021</pub-id><pub-id pub-id-type="pmcid">PMC5967410</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asokan</surname><given-names>S</given-names></name></person-group>. <article-title>Immune issues in elderly with TB</article-title>. <source>Indian J Tuberc</source><year>2022</year>;<volume>69</volume>:<fpage>S241</fpage>&#8211;<lpage>S5</lpage>.<pub-id pub-id-type="pmid">36400517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijtb.2022.10.012</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olmo-Fontanez</surname><given-names>AM</given-names></name><name name-style="western"><surname>Turner</surname><given-names>J</given-names></name></person-group>. <article-title>Tuberculosis in an aging world</article-title>. <source>Pathogens</source><year>2022</year>;<volume>11</volume>:<fpage>1101</fpage>.<pub-id pub-id-type="pmid">36297158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens11101101</pub-id><pub-id pub-id-type="pmcid">PMC9611089</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bansal</surname><given-names>A</given-names></name><name name-style="western"><surname>Arora</surname><given-names>S</given-names></name></person-group>. <article-title>MDR tuberculosis in elderly</article-title>. <source>Indian J Tuberc</source><year>2022</year>;<volume>69</volume>:<fpage>S267</fpage>&#8211;<lpage>S71</lpage>.<pub-id pub-id-type="pmid">36400522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijtb.2022.10.018</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cirillo</surname><given-names>DM</given-names></name><name name-style="western"><surname>Matteelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Penn-Nicholson</surname><given-names>A</given-names></name><name name-style="western"><surname>Rangaka</surname><given-names>MX</given-names></name><name name-style="western"><surname>Ruhwald</surname><given-names>M</given-names></name></person-group>. <article-title>Tests for tuberculosis infection: landscape analysis</article-title>. <source>Eur Respir J</source><year>2021</year>;<volume>58</volume>:<fpage>210016</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00167-2021</pub-id><pub-id pub-id-type="pmid">33875495</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsayed</surname><given-names>SSR</given-names></name><name name-style="western"><surname>Gunosewoyo</surname><given-names>H</given-names></name></person-group>. <article-title>Tuberculosis: pathogenesis, current treatment regimens and new drug targets</article-title>. <source>Int J Mol Sci</source><year>2023</year>;<volume>24</volume>:<fpage>5202</fpage>.<pub-id pub-id-type="pmid">36982277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24065202</pub-id><pub-id pub-id-type="pmcid">PMC10049048</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dheda</surname><given-names>K</given-names></name><name name-style="western"><surname>Mirzayev</surname><given-names>F</given-names></name><name name-style="western"><surname>Cirillo</surname><given-names>DM</given-names></name><etal/></person-group>. <article-title>Multidrug-resistant tuberculosis</article-title>. <source>Nat Rev Dis Primers</source><year>2024</year>;<volume>10</volume>:<fpage>22</fpage>.<pub-id pub-id-type="pmid">38523140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-024-00504-2</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kibret</surname><given-names>KT</given-names></name><name name-style="western"><surname>Moges</surname><given-names>Y</given-names></name><name name-style="western"><surname>Memiah</surname><given-names>P</given-names></name><name name-style="western"><surname>Biadgilign</surname><given-names>S</given-names></name></person-group>. <article-title>Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies</article-title>. <source>Infect Dis Poverty</source><year>2017</year>;<volume>6</volume>:<fpage>7</fpage>.<pub-id pub-id-type="pmid">28093078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40249-016-0214-x</pub-id><pub-id pub-id-type="pmcid">PMC5240443</pub-id></mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Glaziou</surname><given-names>P</given-names></name><name name-style="western"><surname>Lonnroth</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>The impact of social protection and poverty elimination on global tuberculosis incidence: a statistical modelling analysis of Sustainable Development Goal 1</article-title>. <source>Lancet Glob Health</source><year>2018</year>;<volume>6</volume>:<fpage>e514</fpage>&#8211;<lpage>e22</lpage>.<pub-id pub-id-type="pmid">29580761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(18)30195-5</pub-id><pub-id pub-id-type="pmcid">PMC5968370</pub-id></mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saunders</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Evans</surname><given-names>CA</given-names></name></person-group>. <article-title>COVID-19, tuberculosis and poverty: preventing a perfect storm</article-title>. <source>Eur Respir J</source><year>2020</year>;<volume>56</volume>:<fpage>2001348</fpage>.<pub-id pub-id-type="pmid">32444399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.01348-2020</pub-id><pub-id pub-id-type="pmcid">PMC7243392</pub-id></mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wingfield</surname><given-names>T</given-names></name><name name-style="western"><surname>Tovar</surname><given-names>MA</given-names></name><name name-style="western"><surname>Datta</surname><given-names>S</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Evans</surname><given-names>CA</given-names></name></person-group>. <article-title>Addressing social determinants to end tuberculosis</article-title>. <source>Lancet</source><year>2018</year>;<volume>391</volume>:<fpage>1129</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">29595481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)30484-7</pub-id><pub-id pub-id-type="pmcid">PMC7611140</pub-id></mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wigger</surname><given-names>GW</given-names></name><name name-style="western"><surname>Bouton</surname><given-names>TC</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>KR</given-names></name><name name-style="western"><surname>Auld</surname><given-names>SC</given-names></name><name name-style="western"><surname>Yeligar</surname><given-names>SM</given-names></name><name name-style="western"><surname>Staitieh</surname><given-names>BS</given-names></name></person-group>. <article-title>The impact of alcohol use disorder on tuberculosis: a review of the epidemiology and potential immunologic mechanisms</article-title>. <source>Front Immunol</source><year>2022</year>;<volume>13</volume>:<fpage>864817</fpage>.<pub-id pub-id-type="pmid">35432348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.864817</pub-id><pub-id pub-id-type="pmcid">PMC9009367</pub-id></mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>R</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>The global burden of disease attributable to high fasting plasma glucose in 204 countries and territories, 1990-2019: an updated analysis for the global burden of disease study 2019</article-title>. <source>Diabetes Metab Res Rev</source><year>2022</year>;<volume>38</volume>:<fpage>e3572</fpage>.<pub-id pub-id-type="pmid">36001650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dmrr.3572</pub-id></mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pourali</surname><given-names>F</given-names></name><name name-style="western"><surname>Khademloo</surname><given-names>M</given-names></name><name name-style="western"><surname>Abedi</surname><given-names>S</given-names></name><name name-style="western"><surname>Roozbeh</surname><given-names>F</given-names></name><name name-style="western"><surname>Barzegari</surname><given-names>S</given-names></name><name name-style="western"><surname>Moosazadeh</surname><given-names>M</given-names></name></person-group>. <article-title>Relationship between smoking and tuberculosis recurrence: a systematic review and meta-analysis</article-title>. <source>Indian J Tuberc</source><year>2023</year>;<volume>70</volume>:<fpage>475</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">37968054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijtb.2023.04.010</pub-id></mixed-citation></ref><ref id="R42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dabitao</surname><given-names>D</given-names></name><name name-style="western"><surname>Bishai</surname><given-names>WR</given-names></name></person-group>. <article-title>Sex and gender differences in tuberculosis pathogenesis and treatment outcomes</article-title>. <source>Curr Top Microbiol Immunol</source><year>2023</year>;<volume>441</volume>:<fpage>139</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="pmid">37695428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-031-35139-6_6</pub-id></mixed-citation></ref><ref id="R43"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>D</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name></person-group>. <article-title>Burden of type 1 and type 2 diabetes and high fasting plasma glucose in Europe, 1990-2019: a comprehensive analysis from the global burden of disease study 2019</article-title>. <source>Front Endocrinol (Lausanne)</source><year>2023</year>;<volume>14</volume>:<fpage>1307432</fpage>.<pub-id pub-id-type="pmid">38152139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1307432</pub-id><pub-id pub-id-type="pmcid">PMC10752242</pub-id></mixed-citation></ref><ref id="R44"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franco</surname><given-names>JV</given-names></name><name name-style="western"><surname>Bongaerts</surname><given-names>B</given-names></name><name name-style="western"><surname>Metzendorf</surname><given-names>MI</given-names></name><etal/></person-group>. <article-title>Diabetes as a risk factor for tuberculosis disease</article-title>. <source>Cochrane Database Syst Rev</source><year>2024</year>;<volume>8</volume>:<fpage>CD016013</fpage>.<pub-id pub-id-type="pmid">39177079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD016013.pub2</pub-id><pub-id pub-id-type="pmcid">PMC11342417</pub-id></mixed-citation></ref><ref id="R45"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yanqiu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xiaoqing</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Impact of hyperglycemia on tuberculosis treatment outcomes: a cohort study</article-title>. <source>Sci Rep</source><year>2024</year>;<volume>14</volume>:<fpage>13586</fpage>.<pub-id pub-id-type="pmid">38866898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-64525-3</pub-id><pub-id pub-id-type="pmcid">PMC11169383</pub-id></mixed-citation></ref><ref id="R46"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngo</surname><given-names>MD</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>S</given-names></name><name name-style="western"><surname>Ronacher</surname><given-names>K</given-names></name></person-group>. <article-title>Diabetes-associated susceptibility to tuberculosis: contribution of hyperglycemia vs. dyslipidemia</article-title>. <source>Microorganisms</source><year>2021</year>;<volume>9</volume>:<fpage>2282</fpage>.<pub-id pub-id-type="pmid">34835407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/microorganisms9112282</pub-id><pub-id pub-id-type="pmcid">PMC8620310</pub-id></mixed-citation></ref><ref id="R47"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koomen</surname><given-names>LEM</given-names></name><name name-style="western"><surname>Burger</surname><given-names>R</given-names></name><name name-style="western"><surname>van Doorslaer</surname><given-names>EKA</given-names></name></person-group>. <article-title>Effects and determinants of tuberculosis drug stockouts in South Africa</article-title>. <source>BMC Health Serv Res</source><year>2019</year>;<volume>19</volume>:<fpage>213</fpage>.<pub-id pub-id-type="pmid">30943967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12913-019-3972-x</pub-id><pub-id pub-id-type="pmcid">PMC6448237</pub-id></mixed-citation></ref><ref id="R48"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicholson</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Hoddinott</surname><given-names>G</given-names></name><name name-style="western"><surname>Seddon</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>A systematic review of risk factors for mortality among tuberculosis patients in South Africa</article-title>. <source>Syst Rev</source><year>2023</year>;<volume>12</volume>:<fpage>23</fpage>.<pub-id pub-id-type="pmid">36814335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13643-023-02175-8</pub-id><pub-id pub-id-type="pmcid">PMC9946877</pub-id></mixed-citation></ref><ref id="R49"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>P</given-names></name><name name-style="western"><surname>Das</surname><given-names>A</given-names></name><name name-style="western"><surname>Panda</surname><given-names>A</given-names></name><name name-style="western"><surname>Priyadarshani</surname><given-names>A</given-names></name><name name-style="western"><surname>Patro</surname><given-names>BK</given-names></name></person-group>. <article-title>India marching towards TB elimination: how far we are</article-title>. <source>Indian J Tuberc</source><year>2024</year>;<volume>71</volume>:<fpage>213</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">38589126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijtb.2023.06.019</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>